-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | Cantor Fitzgerald | → $38 | Reiterates | → Overweight |
| 12/14/2022 | 111.22% | Stifel | → $29 | Initiates Coverage On | → Buy |
| 12/01/2022 | 82.08% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/06/2022 | 133.07% | BTIG | → $32 | Initiates Coverage On | → Buy |
| 06/16/2021 | 264.17% | HC Wainwright & Co. | $40 → $50 | Maintains | Buy |
| 06/15/2021 | 118.5% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 04/21/2021 | 191.33% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 03/04/2021 | 89.37% | SVB Leerink | $21 → $26 | Maintains | Outperform |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5 → $21 | Maintains | Outperform |
| 10/23/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 10/22/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/06/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/09/2019 | -63.58% | Cantor Fitzgerald | $24 → $5 | Reiterates | → Overweight |
| 06/27/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 05/06/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 10/16/2018 | 147.63% | JMP Securities | $47 → $34 | Maintains | Market Outperform |
| 03/28/2018 | 278.73% | Leerink Swann | $54 → $52 | Maintains | Outperform |
| 03/13/2018 | 293.3% | Leerink Swann | $56 → $54 | Maintains | Outperform |
| 02/09/2018 | 286.02% | Guggenheim | → $53 | Initiates Coverage On | → Buy |
What is the target price for Aclaris Therapeutics (ACRS)?
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Cantor Fitzgerald on February 7, 2023. The analyst firm set a price target for $38.00 expecting ACRS to rise to within 12 months (a possible 176.77% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aclaris Therapeutics (ACRS) is trading at is $13.73, which is within the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | Cantor Fitzgerald | → $38 | Reiterates | → Overweight |
| 12/14/2022 | 111.22% | Stifel | → $29 | Initiates Coverage On | → Buy |
| 12/01/2022 | 82.08% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/06/2022 | 133.07% | BTIG | → $32 | Initiates Coverage On | → Buy |
| 06/16/2021 | 264.17% | HC Wainwright & Co. | $40 → $50 | Maintains | Buy |
| 06/15/2021 | 118.5% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 04/21/2021 | 191.33% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 03/04/2021 | 89.37% | SVB Leerink | $21 → $26 | Maintains | Outperform |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5 → $21 | Maintains | Outperform |
| 10/23/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 10/22/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/06/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/09/2019 | -63.58% | Cantor Fitzgerald | $24 → $5 | Reiterates | → Overweight |
| 06/27/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 05/06/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 10/16/2018 | 147.63% | JMP Securities | $47 → $34 | Maintains | Market Outperform |
| 03/28/2018 | 278.73% | Leerink Swann | $54 → $52 | Maintains | Outperform |
| 03/13/2018 | 293.3% | Leerink Swann | $56 → $54 | Maintains | Outperform |
| 02/09/2018 | 286.02% | Guggenheim | → $53 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | 康託·菲茨傑拉德 | →$38 | 重申 | →超重 |
| 2022年12月14日 | 111.22% | Stifel | →$29 | 開始承保 | →購買 |
| 12/01/2022 | 82.08% | 高盛 | →$25 | 開始承保 | →購買 |
| 10/06/2022 | 133.07% | BTIG | →$32 | 開始承保 | →購買 |
| 06/16/2021 | 264.17% | HC Wainwright公司 | $40→$50 | 維護 | 買 |
| 2021/06/15 | 118.5% | 派珀·桑德勒 | →$30 | 開始承保 | →超重 |
| 04/21/2021 | 191.33% | HC Wainwright公司 | →$40 | 開始承保 | →購買 |
| 03/04/2021 | 89.37% | SVB Leerink | $21→$26 | 維護 | 跑贏大盤 |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5→$21 | 維護 | 跑贏大盤 |
| 2019年10月23日 | - | SVB Leerink | 升級 | 市場表現優於→ | |
| 2019年10月22日 | - | SVB Leerink | 升級 | 市場表現優於→ | |
| 2019年06月09日 | - | JMP證券 | 評級下調 | 市場表現優於→市場表現 | |
| 2019年08月09日 | -63.58% | 康託·菲茨傑拉德 | $24→$5 | 重申 | →超重 |
| 2019年06月27日 | - | SVB Leerink | 評級下調 | 跑贏→市場表現 | |
| 2019年05月06日 | - | SVB Leerink | 開始承保 | →跑贏大盤 | |
| 2018年10月16日 | 147.63% | JMP證券 | $47→$34 | 維護 | 市場表現強於大盤 |
| 2018年3月28日 | 278.73% | 利林克·斯旺 | $54→$52 | 維護 | 跑贏大盤 |
| 2018年03月13日 | 293.3% | 利林克·斯旺 | $56→$54 | 維護 | 跑贏大盤 |
| 2018年02月09日 | 286.02% | 古根海姆 | →$53 | 開始承保 | →購買 |
What is the target price for Aclaris Therapeutics (ACRS)?
Aclaris Treeutics(ACRS)的目標價格是多少？
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Cantor Fitzgerald on February 7, 2023. The analyst firm set a price target for $38.00 expecting ACRS to rise to within 12 months (a possible 176.77% upside). 4 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年2月7日報道了Aclaris治療公司(納斯達克：ACRS)的最新目標價。這家分析公司將目標價定為38美元，預計ACR將在12個月內上漲至(可能上漲176.77%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
Aclaris治療公司(ACRS)的最新分析師評級是多少？
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
對Aclaris治療公司(納斯達克代碼：ACRS)的最新分析師評級由坎託·菲茨傑拉德提供，Aclaris治療公司重申其增持評級。
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Aclaris Treeutics(ACRS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Aclaris治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Aclaris治療公司的上一次評級是在2023年2月7日提交的，所以你應該預計下一次評級將在2024年2月7日左右的某個時候提供。
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
分析師對Aclaris Treeutics(ACRS)的評級正確嗎？
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aclaris Therapeutics (ACRS) is trading at is $13.73, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Aclaris治療(ACRS)評級被重申，目標價在0.00美元至38.00美元之間。Aclaris治療公司(ACRS)目前的交易價格為13.73美元，在分析師的預測範圍內。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧